Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533481 | 0.91 | P2RX7 (0.34) | MAPK1P2RX7 | |
| SCHEMBL15144006 | 0.80 | MAOB (0.33) | MAPK1 | |
| SCHEMBL19764933 | 0.80 | MAPK1 (0.32) | MAPK1P2RX7 | |
| SCHEMBL13726936 | 0.78 | PARP1 (0.41) | MAPK1P2RX7PARP1 | |
| SCHEMBL15132885 | 0.76 | MAPK1 (0.34) | MAPK1P2RX7 | |
| SCHEMBL10158244 | 0.75 | P2RX7 (0.35) | MAPK1P2RX7 | |
| SCHEMBL10158544 | 0.74 | P2RX7 (0.37) | MAPK1P2RX7PARP1 | |
| SCHEMBL25227522 | 0.74 | P2RX7 (0.37) | MAPK1P2RX7 | |
| SCHEMBL30050646 | 0.71 | LMNA (0.36) | MAPK1P2RX7 | |
| SCHEMBL24819195 | 0.71 | LMNA (0.36) | MAPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-28 | — | — | US | disclosed |
| EP-3724189-B1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11673901-B2 | Polycyclic compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11634435-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-12-31 | — | — | US | disclosed |
| CN-111433205-A | Polycyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-2757096-A9 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140296228-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296228-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2757096-A1 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20110028464-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028464-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009062285-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062289-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062288-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062308-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028464-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | MAPK1 1879/4885P2RX7 4071/4885PARP1 364/4885 |
| US-11673901-B2 | Polycyclic compounds as allosteric SHP2 inhibitors | PTPN18, PTPN1, PTPRJ | MAPK1 440/4885P2RX7 890/4885PARP1 4150/4885 |
| US-20140296228-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, POLR1E | MAPK1 1742/4885P2RX7 4177/4885PARP1 533/4885 |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | MAPK1 440/4885P2RX7 890/4885PARP1 4150/4885 |
| US-11634435-B2 | — | PTPN18, PTPN6, PTPN5 | MAPK1 570/4885P2RX7 879/4885PARP1 4727/4885 |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | MAPK1 440/4885P2RX7 890/4885PARP1 4150/4885 |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CCNY, RTF2, POLR2E | MAPK1 2634/4885P2RX7 2690/4885PARP1 231/4885 |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, POLR1E | MAPK1 1742/4885P2RX7 4177/4885PARP1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.